Thus, our findings open the possibility of using synthetic FPR1 antagonists and FPR2/FPR3 agonists to resolve persistent inflammation and subsequent endothelial dysfunction in OSA[45]. This evidence concerns the gene FPR3 and obstructive sleep apnea syndrome.